[go: up one dir, main page]

EP3527225A4 - Composition contenant un anticorps anti-robo4 et un autre agent - Google Patents

Composition contenant un anticorps anti-robo4 et un autre agent Download PDF

Info

Publication number
EP3527225A4
EP3527225A4 EP17860929.3A EP17860929A EP3527225A4 EP 3527225 A4 EP3527225 A4 EP 3527225A4 EP 17860929 A EP17860929 A EP 17860929A EP 3527225 A4 EP3527225 A4 EP 3527225A4
Authority
EP
European Patent Office
Prior art keywords
agent
composition containing
containing anti
robo4 antibody
robo4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17860929.3A
Other languages
German (de)
English (en)
Other versions
EP3527225A1 (fr
Inventor
Yoshitaka Isumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of EP3527225A1 publication Critical patent/EP3527225A1/fr
Publication of EP3527225A4 publication Critical patent/EP3527225A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17860929.3A 2016-10-12 2017-10-11 Composition contenant un anticorps anti-robo4 et un autre agent Withdrawn EP3527225A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016200551 2016-10-12
PCT/JP2017/036721 WO2018070390A1 (fr) 2016-10-12 2017-10-11 Composition contenant un anticorps anti-robo4 et un autre agent

Publications (2)

Publication Number Publication Date
EP3527225A1 EP3527225A1 (fr) 2019-08-21
EP3527225A4 true EP3527225A4 (fr) 2020-06-10

Family

ID=61906233

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17860929.3A Withdrawn EP3527225A4 (fr) 2016-10-12 2017-10-11 Composition contenant un anticorps anti-robo4 et un autre agent

Country Status (4)

Country Link
US (1) US20190300607A1 (fr)
EP (1) EP3527225A4 (fr)
JP (1) JPWO2018070390A1 (fr)
WO (1) WO2018070390A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (fr) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Anticorps et conjugués de ceux-ci
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2021072265A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
WO2023156437A1 (fr) * 2022-02-16 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps monoclonaux humains anti-robo4 et leurs utilisations pour traiter le cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100805A2 (fr) * 2007-02-09 2008-08-21 Genentech, Inc. Anticorps anti-robo4 et utilisations de ceux-ci
WO2013160879A1 (fr) * 2012-04-27 2013-10-31 Daiichi Sankyo Company, Limited Anticorps anti-robo4
JP2013230115A (ja) * 2012-04-27 2013-11-14 Daiichi Sankyo Co Ltd 抗ｒｏｂｏ４抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
JP4723140B2 (ja) 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
WO2008073441A2 (fr) 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions et méthodes de traitement de l'angiogenèse pathologique et de la perméabilité vasculaire
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100805A2 (fr) * 2007-02-09 2008-08-21 Genentech, Inc. Anticorps anti-robo4 et utilisations de ceux-ci
WO2013160879A1 (fr) * 2012-04-27 2013-10-31 Daiichi Sankyo Company, Limited Anticorps anti-robo4
JP2013230115A (ja) * 2012-04-27 2013-11-14 Daiichi Sankyo Co Ltd 抗ｒｏｂｏ４抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C H MEYER ET AL: "Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab", EYE, vol. 25, no. 6, 1 April 2011 (2011-04-01), GB, pages 661 - 672, XP055690173, ISSN: 0950-222X, DOI: 10.1038/eye.2011.66 *
G.S. FALCHOOK ET AL: "Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer", ANNALS OF ONCOLOGY., vol. 24, no. 12, 1 December 2013 (2013-12-01), NL, pages 3004 - 3011, XP055689967, ISSN: 0923-7534, DOI: 10.1093/annonc/mdt395 *
See also references of WO2018070390A1 *

Also Published As

Publication number Publication date
WO2018070390A1 (fr) 2018-04-19
JPWO2018070390A1 (ja) 2019-08-22
US20190300607A1 (en) 2019-10-03
EP3527225A1 (fr) 2019-08-21

Similar Documents

Publication Publication Date Title
EP3581651A4 (fr) Anticorps anti-gprc5d et molécule le contenant
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA44659A (fr) Anticorps anti-tim-3 et compositions
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
EP3449940A4 (fr) Préparation contenant un anticorps
EP3353213A4 (fr) Nouvel anticorps anti-mésothéline et composition le comprenant
EP3375796A4 (fr) Copolymère et composition le contenant
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3359573A4 (fr) Marquage d'anticorps
EP3399956A4 (fr) Compositions cosmétiques contenant des céramides et du cholestérol
EP3307274A4 (fr) Anticorps anti-cd123 et conjugués de ceux-ci
EP3040355A4 (fr) Modificateur d'asphalte et composition d'asphalte le contenant
EP3666729A4 (fr) Composition contenant du nano-soufre et application associée
EP3302561A4 (fr) Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20
EP3307321A4 (fr) Plate-forme d'anticorps multi-spécifiques et procédés associés
EP3310376A4 (fr) Agents thérapeutiques modifiés et compositions associées
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
EP3386986A4 (fr) Conjugués porphyrine d'or-peg et procédés d'utilisation
EP3568016C0 (fr) Composition comprenant des microparticules contenant de la cinméthyline et un autre herbicide
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
BR112017016465A2 (pt) composto heterocíclico e composição farmacêutica que o compreende
EP3412344A4 (fr) Composition d'agent extincteur
EP3373950A4 (fr) Procédés et compositions d'évaluation de spécificités d'anticorps
EP3527225A4 (fr) Composition contenant un anticorps anti-robo4 et un autre agent
EP3650517A4 (fr) Composition retardatrice de flamme et composition de résine retardatrice de flamme la contenant

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190509

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200512

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20200506BHEP

Ipc: A61K 38/02 20060101ALI20200506BHEP

Ipc: C12N 15/09 20060101ALI20200506BHEP

Ipc: C07K 14/71 20060101ALI20200506BHEP

Ipc: A61K 31/7088 20060101ALI20200506BHEP

Ipc: A61K 45/00 20060101ALI20200506BHEP

Ipc: A61P 27/06 20060101ALI20200506BHEP

Ipc: A61P 43/00 20060101ALI20200506BHEP

Ipc: A61K 39/00 20060101ALN20200506BHEP

Ipc: A61P 37/06 20060101ALI20200506BHEP

Ipc: C07K 16/22 20060101AFI20200506BHEP

Ipc: A61P 27/02 20060101ALI20200506BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20220119